<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893801</url>
  </required_header>
  <id_info>
    <org_study_id>PCRT 12-001</org_study_id>
    <nct_id>NCT01893801</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)</brief_title>
  <official_title>A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gayle Jameson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virgina G. Piper Cancer Center - Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pancreatic Cancer Research Team</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy of nab-paclitaxel plus
      cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma
      (PDA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1b/2 open-label pilot study evaluating the preliminary efficacy and safety of
      nab-paclitaxel, cisplatin, and gemcitabine in patients with metastatic pancreatic ductal
      adenocarcinoma.

      An individual cycle of therapy will be defined as Days 1 and 8 every 21 days. Multiple cycles
      may be administered until the patient is withdrawn from therapy.

      Overall response rates as well as individual categories of response (complete response-CR,
      partial response-PR, stable disease-SD and progressive disease-PD) will be determined using
      RECIST 1.1. Time-to-event endpoints, including progression free survival (PFS) and OS
      (overall survival) will be assessed using the Kaplan-Meier method. Evaluation of stable
      disease at 9 weeks will also be assessed. Toxicity (adverse events) will be recorded using
      the NCI CTCAE (v4.0, May 2009).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>1 yr.</time_frame>
    <description>The primary objectives of this study is to pursue treatment of 25 individual patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDA) to evaluate:
Complete response rate as defined by computed tomography (CT) scan using RECIST 1.1 criteria and CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9) down to normal limits (from at least &gt; 2x ULN). We expect to accomplish this in &gt; or = to 5% of patients. When a complete response (CR) is documented, a confirmatory PET scan will be obtained.
If 1 or more of 10 patients demonstrate a complete response (CR), study will continue to enroll to a total of 25 patients.
If intolerable adverse events or no clinical benefit are noted in the first 6 patients, study will discontinue enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate disease control rate</measure>
    <time_frame>9 weeks</time_frame>
    <description>Evaluate disease control rate (CR, PR and SD at 9 weeks) in patients with metastatic PDA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate treatment-related toxicities</measure>
    <time_frame>Over the course of the study</time_frame>
    <description>Evaluate the treatment-related toxicities in this patient population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the change in CA 19-9 or other biomarkers</measure>
    <time_frame>Over the course of the study</time_frame>
    <description>Evaluate the change in CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9) in this patient population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel+Cisplatin+gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle</description>
    <arm_group_label>nab-paclitaxel+Cisplatin+gemcitabine</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle</description>
    <arm_group_label>nab-paclitaxel+Cisplatin+gemcitabine</arm_group_label>
    <other_name>cisplatinum</other_name>
    <other_name>cis-diamminedichloroplatinum</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle</description>
    <arm_group_label>nab-paclitaxel+Cisplatin+gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years of age; male or female.

          -  Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.

          -  Capable of providing informed consent and complying with trial procedures.

          -  Karnofsky Performance Status (KPS) of &gt;/=70%.

          -  Life expectancy &gt;/=12 weeks.

          -  Measurable tumor lesions according to RECIST 1.1 criteria.

          -  Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
             surgically sterile, or practicing adequate birth control methods) for the duration of
             the study. Women of child bearing potential must have a negative serum or urine
             pregnancy test at the Screening Visit and be non-lactating. Both male and female
             patients of reproductive potential must agree to use a reliable method of birth
             control during the study.

        Exclusion Criteria:

          -  Patients must have received no previous radiotherapy, surgery, chemotherapy or
             investigational therapy for the treatment of metastatic disease. Prior treatments in
             the adjuvant setting with gemcitabine and/or 5-FU or gemcitabine administered as a
             radiation sensitizer are allowed, provided at least 6 months have elapsed since
             completion of the last dose and no lingering toxicities are present.

          -  Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of
             study treatment.

          -  Exposure to any investigational agent within 4 weeks prior to initiation of study
             treatment.

          -  Evidence of central nervous system (CNS) metastasis (negative imaging study, if
             clinically indicated, within 4 weeks of Screening Visit).

          -  History of other malignancies (except cured basal cell carcinoma, superficial bladder
             cancer or carcinoma in situ of the cervix) unless documented free of cancer for &gt;/= 5
             years.

          -  Laboratory values: Screening serum creatinine &gt; upper limits of normal (ULN); total
             bilirubin &gt; ULN: alanine aminotransferase (ALT) and AST &gt;/= 2.5 ULN or &gt;/= 5.0 x ULN
             if liver metastases are present; absolute neutrophil count &lt; 1,500/mm3, platelet
             concentration &lt; 100,00/mm3, hematocrit level &lt; 27% for females or &lt; 30% for males, or
             coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT],
             International Normalized Ratio [INR]) &gt; 1.5 x ULN unless on therapeutic doses of
             warfarin.

          -  current, serious, clinically significant cardiac arrhythmias as determined by the
             Investigator.

          -  History of HIV infection.

          -  Active, clinically significant serious infection requiring treatment with antibiotics,
             anti-virals or anti-fungals.

          -  Major surgery within 4 weeks prior to initiation of study treatment. Any condition
             that might interfere with the patient's participation in the study or in the
             evaluation of the study results.

          -  Any condition that is unstable and could jeopardize the patient's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gayle S Jameson, MSN ACNP-BC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scottsdale Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Stoll-D'Astice, MS, CCRP</last_name>
    <phone>(602) 358-8319</phone>
    <email>astoll@td2inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Health Care</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN RN AOCNS</last_name>
      <phone>480-323-1339</phone>
      <email>joschaffer@shc.org</email>
    </contact>
    <investigator>
      <last_name>Gayle S Jameson, MSN ACNP-BC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramesh K Ramanathan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel D Von Hoff, MD FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katy B Schroeder, RN BSN OCN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers - Cancer Institute of New Jersey (CINJ)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Krishnan, RN</last_name>
      <phone>732-235-8996</phone>
      <email>warrieac@cinj.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tatianna Zelinskaya</last_name>
      <phone>732-235-9837</phone>
      <email>zelinska@cinj.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Popllin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vita Medical Associates, PC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Saitta, NP</last_name>
      <phone>610-866-0113</phone>
      <email>nurses@vitahemonc.org</email>
    </contact>
    <contact_backup>
      <last_name>Gulyun Zhou, NP</last_name>
      <phone>610-866-0113</phone>
      <email>nurses@vitahemonc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anna A Niewiarowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pcrt.org</url>
    <description>Additional information about the Pancreatic Cancer Research Team (PCRT)</description>
  </link>
  <link>
    <url>http://www.tgen.org</url>
    <description>Non-profit Organization</description>
  </link>
  <link>
    <url>http://www.td2inc.com</url>
    <description>Related link</description>
  </link>
  <link>
    <url>http://www.seenamagowitzfoundation.org</url>
    <description>Non-profit organization for pancreatic cancer research</description>
  </link>
  <reference>
    <citation>Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.</citation>
    <PMID>21969517</PMID>
  </reference>
  <reference>
    <citation>2013 Gastrointestinal Cancers Symposium. Abstract LBA148. Presented January 25, 2013</citation>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pancreatic Cancer Research Team</investigator_affiliation>
    <investigator_full_name>Gayle Jameson</investigator_full_name>
    <investigator_title>Lead Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>Stage IV pancreatic cancer</keyword>
  <keyword>pancreas</keyword>
  <keyword>pancreatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

